LiquidHALLMARK
Prescription plasma liquid-biopsy assay detecting ctDNA and ctRNA for molecular profiling and treatment selection in advanced cancer.
- Developer
- Lucence
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- Peripheral whole blood
- Molecular modality
- DNA mutation, RNA
- Current version
- LiquidHALLMARK current U.S. configuration (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.